The cost-effectiveness of {beta}-radiation therapy for treatment of in-stent restenosis An analysis at 290-day follow-up
Purpose: We studied the cost-effectiveness of percutaneous coronary intervention (PCI) plus {beta}-radiation (Radiotherapy) vs. PCI alone for treating in-stent restenosis. Methods and materials: We analyzed medical resource data collected at US sites during the Intimal Hyperplasia Inhibition with {beta} In-stent Trial (INHIBIT) to compare the incremental costs between Radiotherapy and PCI alone for each repeat target lesion revascularization (TLR) avoided. Costs were assigned for cardiac-related medical services using the Medicare payer perspective. Results: Radiotherapy increased initial inpatient costs by US$3360 (P<.001). In the Radiotherapy and PCI alone groups, the mean per-patient rates for TLR were 0.13 vs. 0.30 (P=.001), and mean per-patient total costs were US$19,286 vs. US$18,349 (P<.001), respectively. The incremental cost of Radiotherapy relative to PCI alone was US$5512 per TLR avoided, which compares favorably to the observed mean per-patient cost of treating restenosis (US$16,852). Conclusions: {beta}-radiation is a cost-effective adjunct to PCI in treating patients with in-stent restenosis.
- OSTI ID:
- 20650549
- Journal Information:
- Cardiovascular Radiation Medicine, Vol. 3, Issue 2; Other Information: DOI: 10.1016/S1522-1865(02)00157-9; PII: S1522186502001579; Copyright (c) 2003 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 1522-1865
- Country of Publication:
- United States
- Language:
- English
Similar Records
The initial course of in-stent restenosis influences the response to vascular brachytherapy
Beta-radiation therapy for long lesions in native coronary vessels A matched comparison between de novo and in-stent restenotic lesions